Amit Kumar Purchases 21,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 21,000 shares of the stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $2.50 per share, with a total value of $52,500.00. Following the purchase, the chief executive officer owned 630,812 shares of the company’s stock, valued at $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anixa Biosciences Stock Performance

Anixa Biosciences stock opened at $2.48 on Tuesday. The company has a market capitalization of $84.37 million, a PE ratio of -8.00 and a beta of 0.59. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46. The firm has a 50 day moving average price of $2.78 and a 200 day moving average price of $3.08.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities research analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Institutional Trading of Anixa Biosciences

Several hedge funds have recently modified their holdings of ANIX. Cetera Investment Advisers acquired a new position in shares of Anixa Biosciences during the fourth quarter worth about $35,000. Graham Capital Management L.P. acquired a new position in Anixa Biosciences during the 4th quarter worth approximately $81,000. Squarepoint Ops LLC acquired a new position in Anixa Biosciences during the 4th quarter worth approximately $83,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Anixa Biosciences in the 3rd quarter valued at approximately $51,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday. Wall Street Zen lowered shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday. Finally, D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.